

**ASX Announcement | 13 March 2023
Visioneering Technologies (ASX:VTI)**

Visioneering Announces Minimal Exposure to Silicon Valley Bank

Atlanta, Georgia, Sunday, 12 March 2023 (Monday, 13 March 2023 Sydney time): US-based medical device company and producer of the NaturalVue® (etafilcon A) Multifocal 1 Day Contact Lenses **Visioneering Technologies, Inc. (ASX: VTI)** ('**Visioneering**' or '**the Company**') today provided commentary on its current banking relationship with Silicon Valley Bank ("SVB").

On 10 March 2023, the U. S. Federal Deposit Insurance Corp. ("FDIC") took control of SVB. The FDIC announced that insured depositors would have access to their funds by Monday morning, 13 March 2023, US time. Depositors with deposits in excess of the US\$250,000 insured limit will be issued receivership certificates for their uninsured balances. The timing of gaining access to such funds is unknown, if the funds are to become available at all.

Visioneering's deposit accounts held at SVB in excess of the insured limit are less than US\$100,000, which the Company does not believe is a material portion of its cash and cash equivalents. The Company holds the remainder of its investments at another institution. All such investments are backed by the US government and are not exposed to any consequences of a liquidity concern at SVB. Visioneering also has no credit facilities with SVB. Visioneering is monitoring the situation at SVB carefully and does not believe there is any current risk to its business.

Ends.

This release was authorized by the COO & CFO, Brian Lane.

For more information, please contact:

Company	Investor and media relations
Brian Lane COO & CFO Visioneering Technologies, Inc. Email: blane@vtivision.com	Haley Chartres H^CK Tel: +61 423 139 163 Email: haley@hck.digital

About VTI:

Visioneering Technologies Inc. (ASX:VTI) is an innovative eye care company committed to redefining vision. A pioneer in myopia and presbyopia management, VTI merges advanced engineering with a relentless drive to achieve superior results for patients and practitioners. VTI's

flagship product is the NaturalVue® (etafilcon A) Multifocal 1-Day Contact Lens, an extended depth of focus lens that is one of the most significant innovations in the eye care industry in more than 20 years. For more information, please visit www.vtvision.com.

Foreign ownership restrictions:

VTI's CHES Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies, and other factors, many of which are beyond the Company's control (including but not limited to the COVID-19 pandemic), subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events, or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, U.S. commercial market acceptance and U.S. sales of our product, as well as our expectations with respect to our ability to develop and commercialize new products.

Given the current uncertainties regarding the ongoing impact of COVID-19 on the trading conditions impacting VTI, the financial markets, and the health services worldwide, there can be no assurance that future developments will be in accordance with VTI's expectations or that the effect of future developments on VTI will be those anticipated.

Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. VTI does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. VTI may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments, or events could differ materially from those disclosed in the forward-looking statements.

VTI-IR-ASX77